Document is current
Any future updates will be listed below
-
Authors
Tosoian, Jeffrey J. http://orcid.org/0000-0002-7614-9931
Sessine, Michael S.
Trock, Bruce J.
Ross, Ashley E. http://orcid.org/0000-0001-7044-9688
Xie, Cassie
Zheng, Yingye
Samora, Nathan L. http://orcid.org/0000-0003-4158-552X
Siddiqui, Javed
Niknafs, Yashar
Chopra, Zoey http://orcid.org/0000-0002-6349-2431
Tomlins, Scott
Kunju, Lakshmi P.
Palapattu, Ganesh S.
Morgan, Todd M.
Wei, John T.
Salami, Simpa S.
Chinnaiyan, Arul M.
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation (20YOUN11)
SPORE Career Enhancement Program
Rogel Cancer Center Medical Student Scholarship
A. Alfred Taubman Medical Research Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Early Detection Research Network
American Cancer Society
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 5 June 2022
Revised: 16 November 2022
Accepted: 9 December 2022
First Online: 30 December 2022
Competing interests
: JJT and AMC are advisors with equity interest in LynxDx. MSS and YZ are consultants to LynxDx. AMC and SAT are co-inventors on a patent issued to The University of Michigan (UM) on ETS gene fusions in prostate cancer and are included in the royalty distribution stream (managed by UM). The patent is currently licensed to LynxDx.
: Institutional review board approval was obtained at participating sites, and all patients provided informed consent. This study was performed in accordance with the Declaration of Helsinki.
